.3B, trading at NT$72.90 on the TWO. This SniperIQ fundamentals page covers SYN-TECH Chem. & Pharm's valuation (P/E 12.6x, P/B 1.3x), profitability (net margin 20.4%), revenue (NT

What is SYN-TECH Chem. & Pharm's P/E ratio?

SYN-TECH Chem. & Pharm's trailing twelve-month P/E ratio is 12.6x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is SYN-TECH Chem. & Pharm?

SYN-TECH Chem. & Pharm runs a net profit margin of 20.4%, a gross margin of 35.0%, and an operating margin of 24.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does SYN-TECH Chem. & Pharm generate?

SYN-TECH Chem. & Pharm reported revenue of NT

Does SYN-TECH Chem. & Pharm pay a dividend?

SYN-TECH Chem. & Pharm offers a trailing dividend yield of about 5.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is SYN-TECH Chem. & Pharm financially healthy?

SYN-TECH Chem. & Pharm carries a debt-to-equity ratio of 0.09x and a current ratio of 3.41x, with a market beta of -0.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is SYN-TECH Chem. & Pharm a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For SYN-TECH Chem. & Pharm (1777) the key facts are: market cap NT

.3B, P/E 12.6x, revenue NT

Track SYN-TECH Chem. & Pharm's full fundamentals live

Get SYN-TECH Chem. & Pharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.